Drug & intervention

zongertinib

RxCUI 2721604

Clinical trials5

Recruiting3

Related conditions8

Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

5 shown

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without PembrolizumabNCT07486817 · 2026-06-04

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsNCT07195695 · 2026-01-16

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadNCT06324357 · 2024-06-28

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard TreatmentNCT06151574 · 2024-02-09

ACTIVE_NOT_RECRUITING

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)NCT04886804 · 2021-07-02

ACTIVE_NOT_RECRUITING

Conditions being studied

Lung Cancer, Non-squamous, Non-small Cell2 Non-small Cell Lung Cancer2 Colorectal Cancer1 Esophageal Adenocarcinoma1 Gastroesophageal Junction Adenocarcinoma1 Metastatic Breast Cancer1 Metastatic Gastric Adenocarcinoma1 Neoplasm Metastasis1

Research locations

BarcelonaSpain5 MadridSpain5 ParisFrance5 SeoulSouth Korea5 ShanghaiChina5 CologneGermany4 FairfaxVirginia, United States4 GuangzhouChina4 HangzhouChina4 LondonUnited Kingdom4 LyonFrance4 MarseilleFrance4

Leading sponsors

Boehringer Ingelheim5

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.